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ABSTRACT Two ionizing radiation-sensitive (IRS) and
DNA double-strand break (DSB) mutants, sxi-3 and sxi-2,
were shown to be severely deficient in a DNA end binding
activity, similar to a previously described activity of the Ku
autoantigen, correlating with thexrs (XRCC5) mutations. Cell
fusions with xrs-6, another IRS, DSB repair-deficient cell line,
defined these sxi mutants in the XRCC5 group. sr-3 cells have
low expression levels of the p86Ku mRNA. Introduction of the
Ku p86 gene, but not the p70 Ku gene, complemented the IRS,
DNA end binding, and variable(diversity)joining [V(D)J]
recombination signal and codingjunction deficiencies ofsxi-3.
Thus, the p86 Ku gene product is essential for DSB repair and
V(D)J recombination.
DNA double-strand break (DSB) damage occurs spontane-
ously as errors in DNA synthesis, recombination, and mitosis
or may be induced experimentally by ionizing radiation (IR) or
other means. DSBs are deleterious to cells unless repaired. In
mammals, DSB repair is likely to occur by a nonhomologous
end joining pathway. Several mammalian mutants defective in
DSB repair have been identified (reviewed in ref. 1).
Variable(diversity)joining [V(D)J] recombination of B and
T cells has features of DSB repair functions. DSBs may be
intermediates in V(D)J recombination (2-5). Coding junction
products of V(D)J recombination are heterogeneous and can
occur between coding DNA that has little or no homology
(reviewed in ref. 1 and references therein). Coding junction
synthesis and end joining in mammalian cells (6) may be highly
similar to the repair pathway of IR-induced chromosomal
DSBs.
Mutants that have combined defects in DSB repair and
V(D)J recombination have been identified by different routes.
scid (severe combined immunodeficient) mice are profoundly
immunodeficient and have a defect in V(D)J recombination
coding junction formation (7-10). scid cells are severely IR-
sensitive (IRS), specifically containing a DSB repair defect for
IR damage (11-13). Similarly, the IRS, DSB repair-deficient
Chinese hamster ovary (CHO) cell mutants XRCC5 and XR-1
(14) were defective for recombination signal sequence (RSS)
and coding joining of V(D)J recombination (15, 16). Recently
we isolated additional mutants of IR-induced DSB repair in a
screen for IRS (S.E.L., D.M.H., D.M.B., C.R.P., and E.A.H.,
unpublished data). xrs cells are deficient in a DNA end binding
activity (18-20). The Ku autoantigen is a heterodimer that
binds to DNA ends (21). Mapping of the large subunit of Ku
and xrs shows colocalization in a region on human chromo-
some 2 (22, 23).
Here we show the sxi-3 mutant ofDSB repair is defective for
both product formation steps of V(D)J recombination. sxi-3
cells were found to be in the XRCC5 IRS group and were
complemented by the p86Ku gene for DNA repair and re-
combination functions. Thus, Ku must coordinate DSB repair
and V(D)J recombination.
MATERIALS AND METHODS
Transfection and IR Cell Survival. Expression plasmids for
human p70Ku and p86Ku cDNAs were constructed in SRa, a
derivative of pcDL-SRa296 (24). SRa-p7OKu or SRa-p86Ku
(20 ,ug) was transfected into sxi-3 cells grown in 10:1 excess
over pPGKhygromycin by standard calcium phosphate pre-
cipitation and hygromycin selection (Sigma, 200 ,ug/ml). One
hundred to 200 colonies were pooled and replated for IRS tests
at 200 cells per 60-mm plate (13).
DNA End Binding. A 32P-labeled Pvu II-Xma I fragment of
pJH290 was prepared. Nuclear extracts, DNA end binding, and
mobility shift gels were by standard methods (18, 19). Anti-
bodies (1 ,ul of ascites fluid) for supershifting were directly
added to the DNA end binding mixture.
Cell Fusion. DSB mutant and control cell lines were scid
(scSV3, V-3) (13, 25); XRCC5 (sxi-2, sxi-3), xrs-6 (26); XR-1
(27); V79-4, and CHO. Cells were tagged with pPGKhygro-
mycin or pPGKpuromycin by calcium phosphate transfection.
Cell fusions were generated between puromycin-resistant and
hygromycin-resistant cells. Cells (1 x 106) of each fusion
partner were plated into a 60-mm plate for 24 hr, washed four
times with serum-free F12 medium (SF12), then 0.5 ml of PEG
1500 (Boehringer Mannheim) added for 1 min, washed four
times with SF12, incubated for 60-90 min at 37°C, and then
incubated in F12 plus 10% fetal bovine serum (FBS), puro-
mycin (2 ,ug/ml), and hygromycin (350 ,ug/ml). After 24 hr,
fusions were replated at 103 cells per plate in duplicate.
Twenty-four colonies of each fusion were tested for IRr (13).
Methionine Labeling. sxi-3, sxi-3/p86Ku, and LAZ388 (5 x
106 cells) were preincubated with 2 ml of methionine-free
medium plus 10% dialyzed FBS for 1 hr. Three hundred
microcuries of [35S]methionine (1 Ci = 37 GBq) was added for
5 hr. Following a phosphate-buffered saline wash, cells were
lysed on ice in 200 ,ul of 40 mM Tris-HCl, pH 8.0/10 mM
EDTA/0.5 M NaCl/0.5% Nonidet P-40 for 30 min; 100 ,ul of
18% PEG 8000 and 0.5 M NaCl were added, and cells were
spun to remove debris. For immunoprecipitations, GE2-9.5
Abbreviations: DSB, double-strand break; IR, ionizing radiation; RSS,
recombination signal sequence; V(D)J, variable(diversity)joining;
scid, severe combined immunodeficient; s, sensitive (sensitivity); r,
resistant (resistance); mAb, monoclonal antibody(ies); R, recombina-
tion frequency.
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(anti-human p86Ku) was added for 1 hr at 4°C; then 50 ,ul of
protein A-Sepharose suspension was added for 1 hr. Protein A
beads were then washed six times in lysis buffer, boiled in
sample buffer, run on 7.5% SDS/polyacrylamide gels, devel-
oped in EN3HANCE (DuPont), and exposed to x-ray film.
RNA Analysis. Chinese hamster cDNA libraries (Clontech,
and generously provided by G. Gill, University of Massachu-
setts) were screened with human p7OKu and p86Ku probes.
Lambda phage were plaque purified and cDNAs of hamster
p7OKu (aa 85-555) and p86Ku (aa 39-732) were used for
hybridization probes in standard Northern analysis.
V(D)J Recombination. Transfection, isolation of V(D)J re-
combinant products, and analysis of recombination frequencies
have been described (28, 29). DNA sequencing of sxi-3/p86
codingjunctions showed the normal extent ofjunctional deletion.
RESULTS
DNA End Binding Activity Is Deficient in sxi Mutants. The
mutants xrs-5, XR-V9B, and XR-V15B (XRCC5 group) were
defective for a DNA end binding activity associated with Ku
(18-20). Thus, we tested sxi-2 and sxi-3 for DNA end binding
by using mobility shift gel electrophoresis (Materials and
Methods). sxi-2 and sxi-3 extracts were severely deficient in
DNA end binding by this assay (Fig. 1). The parental cell line,
V79-4, and a human cell line, LAZ388, produced normal levels
of complex A. As a control, another DNA-protein complex
(complex B) is not competitively inhibited by excess circular
DNA and appears at the same level in V79-4, sxi-2, and sxi-3
(data not shown; ref. 18). xrs-6 was also deficient in DNA
binding activity compared to the parental cell line, CHO (Fig.
1). Extracts from scid and XR-1 cells contained the DNA end
binding activity at normal levels (data not shown). Thus, sxi-2
and sxi-3 are missing a similar biochemical function for DNA
end binding as XRCC5 group members.
Cell Fusions and Screening of the IRS Phenotype Places
sxi-3 and sxi-2 in the XRCC5 Group. The above results
suggested that sxi-3 and sxi-2 may be defective in XRCC5 gene
products. We tested whether these mutants could complement
other mutant cell lines (scid, XRCC5, XR-1) for DSB repair.
sxi-3, sxi-2, V79-4, scSV3, xrs-6, XR-1, and V-3 cells were
transfected with either pPGKhygro or pPGKpuro to prepare
marked cell lines that could be differentially selected (Mate-
rials andMethods). Cell fusions were formed between different
DSB repair mutant cell lines, and following hygromycin and
puromycin selection, fusion clones were evaluated for IRS.
Puromycin-resistant or hygromycin-resistant DSB repair mu-
tant cells had the same IRS as the untransfected mutant cell
lines (data not shown). We found that fusion of sxi-3 or sxi-2
to V79-4 gave IRr clones, indicating that these mutants were
j+0 <,,69t\#p
Table 1. Complementation of IRS of sxi-2 and sxi-3 by cell fusion
Cell line V79-4 xrs-6 scSV3 V-3 XR-1 sxi-2 sxi-3
sxi-2 + - + + + - -
sxi-3 + - + + + - -
Individual fusion clones were tested for IR (450 rads; 1 rad = 0.01
Gy) cell survival. +, >20% of the cell clones expanded from the fusion
were IRr; -, 0% of the fusion cell clones were IRr, after >20 cell fusion
lines were tested.
recessive and could be complemented for their IRS defects
(Table 1). In addition, fusion of sxi-3 to sxi-2 only yielded IRS
cells, suggesting that these mutants may contain defects in the
same gene. IRr clones were readily observed from each of the
fusions of sxi-3 or sx-2 with XR-1, scSV3, and V-3. IRr clones
were examined in IR survival curves with four IR doses to
confirm that these clones had been complemented for the IRS
defect of either fusion partner (data not shown). In contrast to
the other complementation groups, fusions of either sxi-2 or
sri-3 with xrs-6 were always IRS (Table 1). Fusion cell lines of
sxi-3 and xrs-6 were as defective for DNA end binding as were
the parental mutants (data not shown). Therefore, sxi-3, si-2,
and xrs-6, by definition of the lack of complementation fol-
lowing cell fusion, are members of the XRCC5 group.
Restoration of IRS and DNA Binding Defects of sxi-3 by
p86Ku. We examined whether the sxi mutant phenotypes
could be complemented by the introduction of Ku genes. sxi-3
cells were stably transfected with the human p7OKu and p86Ku
cDNAs cloned into a mammalian expression vector, SRa
(Materials and Methods). Following selection, sxi-3/Ku cells
were examined for IRS in cell survival assays. We found that
transfection of p86Ku restored an IRr phenotype to sxi-3 cells
(Fig. 2). sxi-3/p86Ku cells were significantly more IRr than
sx-3 at every IR dose tested. sxi-2 cells were similarly recon-
stituted for IRr by p86Ku (data not shown). Transfection of
pPGKhygro alone did not change the IRS (sxi-3H). sxi-3 cells
were only weakly complemented by transfection of the p7OKu
expression plasmid.
Increased IRr of sxi-3/p86Ku cells would be expected to
correlate with an increased DNA end binding capacity if a
single gene were responsible for both functions. We prepared
nuclear extracts from sxi-3 cells transfected with p7OKu or
p86Ku and from sxi-3H. With equal quantities of nuclear
protein extracts examined, sxi-3/p86Ku cells reconstituted the
level of DNA end binding observed with the V79-4 control
extracts (Fig. 3A). sxi-3/p70 extracts yielded only a low level of
DNA end binding activity. A mAb (111) raised against human
Ku binds to an epitope of the p86 subunit (30). mAb 111
preincubated with human LAZ388 extracts caused a supershift






FIG. 1. DNA end binding activity is absent in sxi-2 and sxi-3 cells.
Following incubation of nuclear extracts with [32P]DNA (159 bp),
samples were fractionated by mobility shift gel electrophoresis. A
DNA end binding complex, A (A), is shown relative to the uncom-
plexed fragment (F). Complex B (B) is present in V79-4 and sxi
mutants and is not competitively inhibited by excess linear DNA (18).
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FIG. 2. Complementation of
IR defect of sxi-3 by the p86Ku
gene. sxi-3 cells were stably trans-
fected with p86Ku, p7OKu, or
pPGKhygro only. sxi-3H (0), sxi-
3/p86Ku (U), sxi-3/p7OKu (*),
and V79-4 (o) cells were treated






Biochemistry: Boubnov et aL
892 Biochemistry: Boubnov et al.










~ ~ ~ 4
_ L:~--.a - p86KU
-- p70KU,^...
A
A of the sxi-3/p86Ku extract, but not V79-4, was also super-
shifted by 111 (Fig. 3B). mAb 111 or an anti-human p7OKu
mAb (N3H10) does not sufficiently cross-react with the ham-
ster p86Ku by this assay or by immunoprecipitation (data not
shown). Importantly, complexA of V79-4 cells was of reduced
mobility relative to LAZ388 cells loaded in the adjacent lane
(Fig. 3C). Complex A of sxi-3/p86Ku was identical in mobility
to that of human extracts (Fig. 3C). Conversely, the low level
of sxi-3/p7OKu complex A had the mobility of hamster ex-
tracts. Therefore, the mobility of complex A is dictated by the
species of the p86Ku subunit. Human p86Ku promotes a faster
mobility than hamster p86Ku. These experiments show that
sxi-3/p86 cells contain a functionally active p86Ku subunit
expressed from the transfected human gene that is a member
of the DNA binding complex.
sxi-3/p86Ku cells were radiolabeled with [35S]methionine to
determine whether human p86Ku can complex with hamster
p7OKu. We immunoprecipitated cell lysates with GE2-9.5, a
mAb that specifically recognizes the human p86Ku subunit.
GE2-9.5 quantitatively precipitates the p7OKu subunit by its
ability to bind to p86Ku (LAZ388, Fig. 3D). sxi-3/p86Ku
lysates were immunoprecipitated with GE2-9.5, and we ob-
served a coprecipitating 70-kDa protein that is presumably the
hamster p7OKu subunit (Fig. 3D). Equal abundances of p86
and p70 were found by this methodology. sxi-3 cells do not have
any immunoprecipitating material in the p86 and p70 regions.
These data indicate that human p86Ku can stably associate
with hamster p7OKu.
p86Ku mRNA Is Absent in sxi-3. To determine the nature of
Ku defects in sxi-3 and sxi-2 cells, we cloned the Chinese
hamster p86Ku and p70Ku genes by their ability to cross-
hybridize with human p86 and p70 cDNA probes. The isolated
cDNA inserts encoded highly homologous genes to the mouse
and human p7OKu and p86Ku genes byDNA sequencing (data
not shown). A Northern blot prepared with sxi-3 and V79-4
poly(A)+ mRNA was probed with the p86Ku hamster cDNA
probe (Materials and Methods). V79-4 cells displayed a 2.8-kb
Fic. 3. Reconstitution of DNA end binding activity
of sxi-3 by p86Ku. (A) DNA end binding (as in Fig. 1) of
sxi-3 is restored in sxi-3/p86Ku, but not sxi-3/p7OKu. (B)
Supershifting of complex A by antibodies recognizing
Ku epitopes: 111 and GE2-9.5, anti-human p86Ku
monoclonal antibodies (mAb); N3H10, anti-human
p7OKu mAb. (C) Mobility of DNA end binding complex
A upon extended electrophoresis. Rodent and human
refer to the relative position of DNA end binding
complex A for both species in control cells, LAZ388
(human) and V79-4 (Chinese hamster). (D) [35S]Methi-
onine radiolabeling and GE2-9.5 immunoprecipitation
of s_Yi-3/p86Ku, LAZ388, and sxi-3 lysates.
mRNA that was not present in the sxi-3 lane despite equal
loading determined by reprobing with glyceraldehyde-3-
phosphate dehydrogenase (Fig. 4). s;i-3 and V79-4 had approx-
imately the same levels ofp7OKu mRNA. p86Ku gene expression
was undetectable in ;xi-2 cell Northern blots, whereas p7OKu
mRNA was at wild-type levels (data not shown).
V(D)J Recombination RSS and Coding Junction Defects of
s*i-3 Are Restored by p86Ku. We examined whether sxi-3 and
sxi-2 affected RSS and/or coding junction formation by co-
transfection of V(D)J recombination templates with RAG1
and RAG2 to stimulate recombination (28, 29). RSS junction
formation, measured with pJH200, was dramatically reduced
in sxi-3 (R = 0.068% ± 0.037%) relative to V79-4 (R = 1.25%
± 0.63%) (Table 2). Only 21-44% of the RSS-RSS fusions in
sxi-3 were precise. sxi-3 also had severely diminished coding
junction formation (R = 0.016% ± 0.001%) compared to
V79-4 (R = 0.73% ± 0.18%). sxi-2 reduced RSS and coding
junction formation by 27- and 17-fold, respectively (data not
shown). Importantly, RSS joining was complemented by
p86Ku (sxi-3/p86Ku, R = 1.01% ± 0.23%) relative to negative
and positive controls: sxi-3 (0.068% ± 0.037%) and V79-4





FIG. 4. Northern analysis ofsxi-3 for Ku gene expression. Poly(A)+
prepared from sxi-3 and V79-4 was evaluated for p86Ku and p70Ku
expression. The Northern blot was probed sequentially with hybrid-
ization probes for p86Ku, p7OKu, and control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes. Escherichia coli size
markers (kilobases) are shown.
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Table 2. V(D)J recombination deficiencies of sxi-3 mutant and complementation by p86Ku
Cell line Exp. Ampr* Ampr + Camrt R, %t Average§ ApaLls1
RSS joining (pJH200)
V79-4 1 334,000 3200 0.96 1.25 ± 0.63 19/21
2 294,000 2400 0.82
3 204,000 4040 1.98
sxi-3 1 9,000 5 0.056 0.068 ± 0.037 8/18
2 23,000 25 0.109
3 5,100 2 0.039
sxi-3/p86Ku 1 17,000 128 0.75 1.01 ± 0.23 21/21
2 48,100 545 1.13
3 25,800 300 1.16
sxi-3/p7OKu 1 12,800 20 0.16 0.15 ± 0.065 4/ 8
2 13,100 28 0.21
3 6,200 5 0.081
Coding joining (pJH290)
V79-4 1 129,000 1200 0.93 0.73 ± 0.18
2 143,000 800 0.56
3 67,000 410 0.61
4 26,200 215 0.82
sxi-3 1 109,000 18 0.017 0.016 ± 0.001
2 68,000 10 0.015
sxi-3/p86Ku 1 319,000 1240 0.39 0.39 ± 0.01
2 203,000 765 0.38
sxi-3/p7OKu 1 77,000 20 0.026 0.040 ± 0.019
2 38,000 20 0.053
*Ampicillin (100 ,ug/ml)-resistant bacterial colonies.
tCamr + Ampr, chloramphenicol (20 ,ug/ml)- and ampicillin (100 ,ug/ml)-resistant colonies.
*[(Camr + Ampr)/Ampr] x 100.
§Average ± SD.
1% correct joins determined from ApaLl restriction digests.
formed with an increased precision, as assessed by ApaLls. In
contrast, sxi-3/p70Ku showed only marginal complementation
of RSS junction frequency and fidelity. The R values of coding
junctions were also complemented in sxi-3/p86Ku cells (R =
0.39% ± 0.01%) compared to sxi-3 (R = 0.016% ± 0.001%).
In this case, V79-4 controls yielded higher values for pJH290
(0.73% ± 0.18%). sxi-2/p86Ku cells that were IRr and DNA
end binding-positive (data not shown) also restored RSS and
coding joining proficiency (R = 0.80% ± 0.49% and 0.86% ±
0.18%) relative to sxi-2 (R = 0.045% ± 0.014% and 0.053% ±
0.035%). Thus, p86Ku complements the V(D)J recombination
deficiency like the IRS andDNA end binding properties ofsxi-3
and sxi-2.
DISCUSSION
This study defines sxi-3 and sxi-2 as members of the XRCC5
group, deficient in a DNA end binding activity and defective
in RSS and coding junction product synthesis of V(D)J re-
combination. Introduction of the p86Ku gene complemented
all of the mutant phenotypes, including IR, DNA end binding,
and RSS and coding junction formation of V(D)J recombina-
tion (Figs. 2 and 3, Table 2, and data not shown). These data
identify p86Ku as an essential factor of V(D)J recombination
and DSB repair.
Several experiments strongly suggest that the 86-kDa Ku
gene product is directly responsible for the DSB repair, V(D)J
recombination, and DNA end binding defects of these sxi
mutants. We have demonstrated a very strong correlation
between the repair and recombination characteristics of sxi-
3/p86Ku (Fig. 2 and Table 2) and the biochemical properties
of DNA end binding complexes that were shown to be absent
in sxi-3 (Fig. 3). Our observations are in concert with previous
data indicating that the DNA end binding complex is Ku in
mammalian cells. Purified Ku, consisting of only the 86- and
70-kDa subunits, binds to DNA ends in vitro and has similar
properties to the DNA end binding complex that we have
described here (32). Supershifting with an anti-human p86Ku
antibody and the mobility of the reconstituted DNA binding
complex indicated that human p86Ku is a constituent of the
complex found in sxi-3/p86Ku cells (Fig. 3 B and C). Inde-
pendent of the biochemical data, p86Ku mRNA was not
detectably produced in sxi-3 and sxi-2 and these cell lines do not
complement one another in cell fusions (Table 1). Importantly,
human p86Ku colocalizes with xrs, another XRCC5 mutant
(23). xrs cells are restored for IRS and V(D)J recombination
defects by microcell-mediated transfer of human chromosome
2 (15, 33). During the publication of this work, the repair and
recombination defects of xrs-6 cells were shown to be com-
plemented by p86Ku (34). Our work with sxi mutants corrob-
orates these findings. We also found that xrs-6 could be
reconstituted for V(D)J recombination RSS and coding junc-
tion formation by p86Ku, but not p70Ku, further supporting
the correlation between XRCC5 mutants and p86Ku.
Our data also strongly suggest that the 70-kDa Ku gene
product is not mutated or altered in the XRCC5 group, even
though the DNA end binding complex that includes the p7OKu
gene product is absent (20). Introduction of the p70 Ku subunit
was unable to significantly increase the level of complemen-
tation of IRS, V(D)J recombination product formation, or
DNA end binding (Figs. 2 and 3 and Table 2). Our preliminary
data suggest that sxi-3, sxi-2, and xrs normally produce the
p70Ku subunit because p70Ku mRNA is expressed as in
control cells. At least for sxi-3 cells, a p7OKu protein is
produced and only appears in the DNA end binding complex
when a functional p86Ku is also present (Fig. 3).
V(D)J Recombination Complementation Groups. The
V(D)J recombination pathway requires gene products that are
lymphoid cell-restricted as well as several that are expressed in
other cell types and may be ubiquitous (1). To date, three
complementation groups (scid, XR-1, and XRCC5) required
in the combined DNA repair and V(D)J recombination func-
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tions have been reported. Several criteria, including those in
this study, support the conclusion that three separate genes are
represented in these groups. sxi-3 and sxi-2 are distinct from
scid and XR-1 based on the IR complementation tests from the
cell fusions (Table 1). Likewise, the determination of V(D)J
recombination properties of sxi-3 and sxi-2 differentiate these
mutants from scid. We observed that coding and RSS junction
formation were defective for both mutants (Table 2). This
same recombination feature of both junctions being affected
had previously been reported for xrs-6 and xrs-5 (15, 16). For
scid and V-3, there is a selective deficiency in coding junction
formation (9, 25, 35). Because there are now established to be
similar repair and recombination properties of four indepen-
dent mutants in XRCC5 group compared to the two mutants
of the scid group, Ku and scid gene products are very likely not
to be allelic variations of the same gene. Furthermore, XR-1
and scid cells have normal levels of the DNA end binding
activity (refs. 18-20 and this study), and p86Ku and p70Ku
genes map to different chromosomes from scid or XR-1 (1).
Because Ku exists as a heterodimer in cells, p7OKu muta-
tions may be defective in DSB repair and V(D)J recombina-
tion. The 70-kDa subunit binds to DNA, even in the absence
of p86Ku (refs. 21 and 36 and references therein). Therefore,
p7OKu may provide the DNA binding activity critical to these
functions. Ku is associated with a protein kinase (DNA-PK) in
mammalian cells (37, 38). The kinase is activated by DNA
ends, presumably via the associated Ku heterodimers. Teth-
ering of an activatible protein kinase is very likely to have
important ramifications for DSB repair and V(D)J recombi-
nation. DNA-PK may phosphorylate repair and recombination
proteins to modulate their activity.
Ku Function in DSB Repair and V(D)J Recombination. Ku
could be used at initiation or at product formation steps in
V(D)J recombination. Defects at both stages of the reaction
may be expected to decrease the R value for detecting either
of the recombination products. Our data and previous reports
are strongly supportive of a role ofKu in V(D)J recombination
product formation instead of the initiation of V(D)J recom-
bination. Ku associates with ends of DNA with high affinity
(39). Although the actual end structures for V(D)J recombi-
nation and DSB repair are not documented fully, in both cases
these ends are likely to have significant variability. Impor-
tantly, Ku is able to recognize many variations in DNA
structure by binding to the transition of single-stranded and
double-stranded DNA or hairpins (17, 31, 40, 41). Thus, Ku is
more likely to play a role at intermediate stages of V(D)J
recombination, where DSBs are formed and need to be
repaired. For DSB repair, the appearance of damaged DNA
ends may signal the recognition by Ku.
Ku may associate with the chromosomal regions of V(D)J
recombinase activity by passive copositioning on the DNA or
by association with other recombination components. Ku can
translocate along DNA to reach a DSB (17, 40, 41). Second,
due to its strong affinity for DNA ends, Ku complexes could
displace other proteins from DNA ends in the reaction. The
substitution of Ku complexes for preexisting structures may
serve to prepare the DNA ends for processing or joining.
Because coding ends and RSS ends are metabolized differ-
ently, additional factors such as scid and XR-1 must contribute.
Identification of one Ku subunit as an important player in
these processes will accelerate the understanding of repair and
recombination pathways overall.
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